



Patent Application

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. of: Thompson, Paul J. Art Group: 3738
Serial No.: 10/775,961 Examiner: Paul Prebilit
Filed: February 10, 2004 Atty. Docket: 23,369-162
For: Braided Composite Prosthesis

TERMINAL DISCLAIMER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Boston Scientific Scimed, Inc. (formerly known as Schneider (USA) Inc), a corporation organized and existing under the laws of the State of Minnesota, and having a principal office located at One Scimed Place, Maple Grove, Minnesota 55311, is owner of the entire right, title and interest in and to the above-identified patent application and the underlying invention, by virtue of an assignment from the inventor, recorded in the U.S. Patent and Trademark Office July 29, 1996 on Reel 8055, beginning at Frame 0823. By virtue of that same assignment, Boston Scientific Scimed, Inc. also is the owner of the entire right, title and interest in and to U.S. Patent No. 6,689,162 issued February 10, 2004, and Patent No. 6,019,786 issued February 1, 2000.

Boston Scientific Scimed, Inc. also is the owner of the entire right, title and interest in and to U.S. Patent No. 6,592,617 issued July 15, 2003, U.S. Patent No. 6,342,068 issued January 29, 2002, and U.S. Application Serial No. 10/619,888 filed July 15, 2003, by virtue of an assignment from the inventor, recorded in the U.S. Patent and Trademark Office July 29, 1996 on Reel 8055, beginning at Frame 0842.

Boston Scientific Scimed, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full

03/04/2005 SSESHE1 00000011 10775961 130.00 OP
02 FC:1814

statutory term of said U.S. Patent No. 6,689,162, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that said patent so granted and said U.S. Patent No. 6,689,162 are commonly owned, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Boston Scientific Scimed, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of said U.S. Patent No. 6,019,786, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that said patent so granted and said U.S. Patent No. 6,019,786 are commonly owned, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Boston Scientific Scimed, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of said U.S. Patent No. 6,592,617, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that said patent so granted and said U.S. Patent No. 6,592,617 are commonly owned, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Boston Scientific Scimed, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of said U.S. Patent No. 6,342,068, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that said patent so granted and said U.S. Patent No. 6,342,068 are commonly owned, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

Boston Scientific Scimed, Inc. hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of any patent granted on said U.S. Application Serial No. 10/619,888, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for

and during such period that said patent so granted and such patent granted on said U.S. Application Serial No. 10/619,888 are commonly owned, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantee, its successors or assigns.

The undersigned is an attorney of record in the above-identified application, and in that capacity is executing this Terminal Disclaimer.


A check in the amount of \$130.00 is enclosed, in payment of the fee for filing this Disclaimer.

The Commissioner is authorized to charge any additional fee that might be required, or to credit any overpayment, to Deposit Account No. 12-0449.

Respectfully submitted,

Boston Scientific Scimed, Inc.

Date: February 28, 2005

By: 
Frederick W. Niebuhr
Registration No. 27,717
Customer No. 23452

CERTIFICATE OF MAILING

Pursuant to 37 C.F.R. 1.8, I hereby certify that this Terminal Disclaimer in U.S. Patent Application Serial No. 10/775,961 is being deposited with the U.S. Postal Service as first class mail, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of deposit indicated below.

Date: February 28, 2005

By: 
Geraldyn M. Vita